Cardiovascular prevention—end of the road for niacin?

Residual macrovascular risk in 2013: what have we learned?

(2014) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients

(2013) S. Matthijs Boekholdt et al.   CIRCULATION

CRTH2 Is A Critical Regulator of Neutrophil Migration and Resistance to Polymicrobial Sepsis

(2012) M. Ishii et al.   JOURNAL OF IMMUNOLOGY

Is it time to revise the HDL cholesterol hypothesis?

(2012) Daniel J Rader et al.   NATURE MEDICINE

Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathophysiology of Diet- and Age-Induced Diabetes in Mice

(2011) Jun Yoshino et al.   Cell Metabolism

Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells

(2011) Martina Lukasova et al.   JOURNAL OF CLINICAL INVESTIGATION

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION